ESR1 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), making hormone therapy and HER2-targeting drugs not useful for treatment [1,2].